Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects

European Journal of Pharmaceutical Sciences

Volumn 26, Issue 3-4, 2005, Pages 295-306

  Krzyzanski, Wojciech ^a   Jusko, William J ^a   Wacholtz, Mary C ^b   Minton, Neil ^b   Cheung, Wing K ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cell lifespans; Epoetin alpha; Indirect response models; Pharmacodynamics; Pharmacokinetics

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; KINETICS; LIFESPAN; MALE; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE;

ADOLESCENT; ADULT; EPOETIN ALFA; ERYTHROCYTE COUNT; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 24644441758     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.06.010     Document Type: Article

References (44)

1. R. Abels Erythropoietin for anemia in cancer patients Eur. J. Cancer 29A Suppl. 2 1993 S2 S8
2. H. Akaike A new look at the statistical model identification IEEE Trans. Autom. Contr. AC-19 1974 716 723
3. N.I. Ashai, E.P. Paganini, and J.M. Wilson Intravenous versus subcutaneous dosing of Epoetin: a review of the literature Am. J. Kidney Dis. 22 Suppl. 1 1993 23 31
4. D.C. Case Jr., R.M. Bukowski, R.W. Carey, E.H. Fishkin, D.H. Henry, R.J. Jacobson, S.E. Jones, A.M. Keller, J.W. Kugler, C.R. Nichols, S.E. Salmon, R.T. Silver, A.M. Storniolo, G.L. Wampler, C.M. Dooley, K.M. Larholt, R.A. Nelson, and R.I. Abels Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy J. Natl. Cancer Inst. 85 1993 801 816
5. S. Chapel, P. Veng-Pedersen, R.J. Hohl, R.L. Schmidt, E.M. McGuire, and J.A. Widness Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway J. Pharmacol. Exp. Ther. 298 2001 820 824
6. S.H. Chapel, P. Veng-Pedersen, L. Schmidt, and J.A. Widness A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep J. Pharmacol. Exp. Ther. 295 2000 346 351
7. W.K. Cheung, B.L. Goon, M.C. Guilfoyle, and M.C. Wacholtz Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects Clin. Pharmacol. Ther. 64 1998 412 423
8. W. Cheung, K. Gunawardena, and N. Minton Pharmacokinetics and pharmacodynamics of Epoetin alfa once weekly and three times weekly Eur. J. Clin. Pharmacol. 57 2001 411 418
9. A.D. D'Andrea, H.F. Lodish, and G.G. Wong Expression cloning of the murine erythropoietin receptor Cell 57 1989 277 285
10. D.Z. D'Argenio, and A. Schumitzky A program package for simulation and parameter estimation in pharmacokinetics Comput. Programs Biomed. 9 1979 115 134
11. N.L. Dayneka, V. Garg, and W.J. Jusko Comparison of four basic models of indirect pharmacodynamic responses J. Pharmacokin. Biopharm. 21 1993 457 478
12. G.D. Demetri, M. Kris, J. Wade, L. Degos, D. Cella Procrit Study Group Quality-of-life benefit in chemotherapy patients treated with Epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study J. Clin. Oncol. 16 1998 3412 3425
13. J.C. Egrie, T.W. Strickland, J. Lane, K. Aoki, A.M. Cohen, R. Smalling, G. Trail, F.K. Lin, J.K. Browne, and D.K. Hines Characterization and biological effects of recombinant human erythropoietin Immunobiology 72 1986 213 224
14. K.K. Flaharty, J. Caro, A. Earsley, J.J. Whalen, E.M. Morris, T.D. Bjornsson, and P.H. Vlasses Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men Clin. Pharmacol. Ther. 47 1990 557 564
15. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston, B. Sarokhan, E. Winer, and L.H. Einhorn Clinical evaluation of once-weekly dosing of Epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J. Clin. Oncol. 19 2001 2875 2882
16. M. Gibaldi, and D. Perrier Pharmacokinetics 1982 Marcel Dekker New York
17. J. Glaspy, R. Bukowski, D. Steinberg, C. Taylor, S. Tchekmedyian, S. Vadhan-Raj Procrit Study Group Impact of therapy with Epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice J. Clin. Oncol. 15 1997 1218 1234
18. Hayashi, N., Kinoshita, H., Yukawa, E., Higuchim S., 1998. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. Br. J. Clin. Pharmacol. 46, 11-19.
19. M. Kato, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats J. Pharmacol. Exp. Ther. 283 1997 520 527
20. S.A. Killmann, E.P. Cronkite, T.M. Fliedner, and V.P. Bond Mitotic indices of human bone marrow cells. III. Duration of some phases of erythrocytic and granulocytic proliferation computed from mitotic indices Blood 24 1964 267 280
21. M.J. Koury, and M.C. Bondurant The molecular mechanism of erythropoietin action Eur. J. Biochem. 210 1992 649 663
22. W. Krzyzanski, R. Ramakrishnan, and W.J. Jusko Basic pharmacodynamic models for agents that alter production of natural cells J. Pharmacokin. Biopharm. 27 1999 467 489
23. T.R. Lappin, and I.N. Rich Erythropoietin - the first 90 years Clin. Lab. Haematol. 18 1996 137 145
24. T.J. Littlewood, E. Bajetta, J.W.R. Nortier, E. Vercammen, B. Rapoport Epoetin Alfa Study Group Effects of Epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J. Clin. Oncol. 19 2001 2865 2874
25. M. Loeffler, K. Pantel, H. Wulff, and H.E. Wichmann A mathematical model of erythropoiesis in mice and rats. Part 1: structure of the model Cell Tissue Kinet. 22 1989 13 30
26. H. Ludwig, E. Fritz, H. Kotzmann, P. Hocker, H. Gisslinger, and U. Barnas Erythropoietin treatment of anemia associated with multiple myeloma N. Engl. J. Med. 322 1993 1693 1699
27. I.C. Macdougall, D.E. Roberts, G.A. Coles, and J.D. Williams Clinical pharmacokinetics of Epoetin (recombinant human erythropoietin) Clin. Pharmacokinet. 20 1991 99 113
28. A. Major, C. Bauer, C. Breymann, A. Huch, and R. Huch rh-Erythropoietin stimulates immature reticulocyte release Br. J. Haematol. 87 1994 605 608
29. S.B. McKenzie Textbook of Hematology 1996 Williams & Wilkins Baltimore
30. T. Papayannopoulou, and J. Abkowitz Biology of erythropoiesis, erythroid differentiation and maturation R. Hoffman E.J. Benz S.J. Shattil B. Furie H.J. Cohen Hematology. Basic Principles and Practice 1995 Churchill Livingstone New York
31. E. Radwanski, A. Chakraborty, S. Van Wart, R.D. Huhn, D.L. Cutler, M.B. Affrime, and W.J. Jusko Pharmacokinetics and leukocyte responses of recombinant human interlukin-10 Pharm. Res. 15 1998 1895 1901
32. R. Ramakrishnan, W.K. Cheung, F. Farrell, M. Kelley, L. Jolliffe, and W.J. Jusko Pharmacokinetic and phramacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous single dose administrations in cynomolgus monkeys J. Pharmacol. Exp. Ther. 306 2003 324 331
33. R. Ramakrishnan, W.K. Cheung, M.C. Wacholtz, N. Minton, and W.J. Jusko Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers J. Clin. Pharmacol. Ther. 44 2004 991 1002
34. K. Sawada, S.B. Krantz, C.-H. Dai, S.T. Koury, S.T. Horn, A.D. Glick, and C.I. Civin Purification of human blood burst-forming units - erythroid and demonstration of the evolution of erythropoietin receptors J. Cell Physiol. 142 1990 219 230
35. K. Sawada, S.B. Krantz, J.S. Kans, E.N. Dessypris, S. Sawyer, A.D. Glick, and C.I. Civin Purification of human colony-forming units - erythroid and demonstration of specific binding of erythropoietin J. Clin. Invest. 80 1987 357 366
36. S.T. Sawyer, and W.D. Hankins The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation Proc. Nat. Acad. Sci. U.S.A. 90 1993 6849 6853
37. S.T. Sawyer, and K. Penta Association of JAK2 and STAT5 with erythropoietin receptors J. Biol. Chem. 271 1996 32430 32437
38. S.T. Sawyer, and M.J. Koury Erythropoietin requirement during terminal erythroid differentiation: the role of surface receptors for erythropoietin J. Cell Biol. 105 1987 1077 (Abstract)
39. A. Sharma, W.F. Ebling, and W.J. Jusko Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena J. Pharm. Sci. 87 1998 1577 1584
40. D. Shasha, M.J. George, and L.B. Harrison Once-weekly dosing of Epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy Cancer 98 2003 1072 1079
41. D.E. Uehlinger, F.A. Goth, and L.B. Sheiner A pharmacodynamic model of erythropoietin therapy for uremic anemia Clin. Pharmacol. Ther. 51 1992 76 89
42. P. Veng-Pedersen, and W.R. Gillespie A system approach to pharmacodynamics I: theoretical framework J. Pharm. Sci. 77 1998 39 47
43. A. Xenocostas, W.K. Cheung, C. Zakszewski, M. Kelly, A. Lutynski, M. Crump, J.H. Lipton, T.L. Kiss, and H. Messner The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin Exp. Hematol. 30 Suppl. 2002 42
44. H. Youssoufian, G. Longmore, D. Newmann, A. Yoshimura, and H. Lodish Structure, function and an activation of erythropoietin receptor Blood 81 1993 223 236